Respirerx Pharmaceuticals Inc Quick Ratio (RSPI) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Respirerx Pharmaceuticals Inc   (RSPI)

Respirerx Pharmaceuticals Inc 's Quick Ratio

RSPI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry 599 other companies have achieved higher Quick Ratio than Respirerx Pharmaceuticals Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 4571 to 5601.

Explain Quick Ratio?
How much Cash & cash equivalents RSPI´s has?
What are RSPI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RSPI Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 11.25 % 14.76 % 5.68 % 22.68 % 22.5 %
Y / Y Cash & cash equivalent Change 34761.9 % -45.24 % -93.71 % -89.21 % -99.93 %
Quick Ratio MRQ 0 0 0 0 0
RSPI's Total Ranking # 5601 # 4571 # 5449 # 5082 # 5657
Seq. Current Liabilities Change -0.63 % 17.17 % -8.31 % 4.21 % 2.5 %
Seq. Cash & cash equivalent Change 5205.07 % 56.82 % 46.67 % 185.71 % -91.67 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 600
Healthcare Sector # 1206
Overall Market # 5601


Quick Ratio Statistics
High Average Low
0.08 0.01 0
(Jun 30 2016)   (Jun 30 2019)




Financial Statements
Respirerx Pharmaceuticals Inc 's Current Liabilities $ 12 Millions Visit RSPI's Balance sheet
Respirerx Pharmaceuticals Inc 's Cash & cash equivalent $ 0 Millions Visit RSPI's Balance sheet
Source of RSPI's Sales Visit RSPI's Sales by Geography


Cumulative Respirerx Pharmaceuticals Inc 's Quick Ratio

RSPI's Quick Ratio for the trailling 12 Months

RSPI Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 13.42 % 16.12 % 18.61 % 23.01 % 23.98 %
Y / Y Cash & cash equivalent TTM Growth 241.58 % -99.1 % -98.93 % -95.54 % -94.21 %
Quick Ratio TTM 0 0 0 0 0
Total Ranking TTM # 4304 # 4268 # 4297 # 4261 # 5199
Seq. Current Liabilities TTM Growth 2.73 % 3.62 % 1.31 % 5.17 % 5.18 %
Seq. Cash & cash equivalent TTM Growth 2377.85 % -27.08 % -75.68 % -22.27 % -93.5 %

Quick ratio ranking by company, industry and sector >> Back to RSPI Financial Strength Comparisons >> Go to Compare RSPI Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the decrease in Current Liabilities in the Q2 2023 to $12.21 millions, cumulative Quick Ratio